New cancer drug combo enters first human tests
Disease control
Completed
This early-stage study tested a new drug called AGEN1777, both by itself and combined with an existing immunotherapy drug, in 25 patients with advanced solid tumors that had stopped responding to standard treatments. The main goal was to find a safe dose and understand how the bo…
Phase: PHASE1 • Sponsor: Agenus Inc. • Aim: Disease control
Last updated Mar 30, 2026 14:34 UTC